Interaction between carbamazepine and fluvoxamine

Fritze, J.; Unsorg, B.; Lanczik, M.

doi:10.1111/j.1600-0447.1991.tb03200.x

Cited by 77 publications

(24 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specifically, several ADs of the SSRI family are inhibitors of several isoenzymes of the cytochrome P450 system. These include fluoxetine, paroxetine, and fluvoxamine (107)(108)(109). Sertraline and citalopram are less likely to have pharmacokinetic interactions with AEDs (71).…”

Section: Pharmacokinetic Interactions Between Ads and Aedsmentioning

confidence: 99%

Depression in Epilepsy: A Common but Often Unrecognized Comorbid Malady

Kanner

Palac

2000

Epilepsy & Behavior

152

View full text Add to dashboard Cite

Section: Pharmacokinetic Interactions Between Ads and Aedsmentioning

confidence: 99%

Depression in Epilepsy: A Common but Often Unrecognized Comorbid Malady

Kanner

Palac

2000

Epilepsy & Behavior

152

View full text Add to dashboard Cite

“…CBZ is metabolized by the P450 3A isoenzymes (244,246), which are believed to be inhibited by fluoxetine, fluvoxamine, sertraline, and nefazodone (244). A normal volunteer study demonstrated elevated CBZ levels after concomitant medication with fluoxetine (254), and adverse events have been reported, with raised plasma concentrations of CBZ, with fluoxetine (255,256), fluvoxamine (257,258), sertraline (259), and nefazodone (260). Raised levels have also been reported with viloxazine (261).…”

Section: Interactionsmentioning

confidence: 99%

Depression in Epilepsy: Etiology, Phenomenology, and Treatment

1999

View full text Add to dashboard Cite

Summary: A history of depression or depressive symptomatology has been reported in up to two-thirds of patients with medically intractable epilepsy, whereas community studies have demonstrated affective disorder only in a quarter of these patients. Depression has been reported peri-and interictally. However, differentiation may be difficult in patients with frequent seizures. Most authors have found no correlation between depression and epilepsy variables. However, complex partial seizures, especially of temporal lobe origin, appear to be etiologic factors, particularly in men with left-sided foci. Depression is also more common in patients treated with polytherapy especially with barbiturates, phenytoin, and vigabatrin. Depression has also been described de novo after temporal lobectomy. Psychosocial factors also play a part, but underlying risk factors (e.g., genetic, endocrine and metabolic) may explain the increased rates of depression in people with epilepsy compared to those with other neurologic and chronic medical conditions. The depression appears to be endogenous. Patients tend to exhibit fewer neurotic traits and more psychotic symptoms such as paranoia, delusions, and persecutory auditory hallucinations. Treatment approaches include psychotherapy, rationalization of antiepileptic drug medication, antidepressant treatment, and ECT. The tricyclic and related antidepressants appear to be epileptogenic, especially in people at high risk (personal or family history of seizures, abnormal pretreatment EEG, brain damage, alcohol or substance abuse/withdrawal and concurrent use of CNS-active medication). Seizures tend to occur early in treatment or after dose increments, especially if rapidly titrated. There is little evidence that the newer antidepressants, e.g., selective serotonin reuptake inhibitors, moclobemide, venlafaxine, or nefazodone are more epileptogenic than placebo.

show abstract

“…Drug interactions that increase the concentrations of carbamazepine or carbamazepine 10,11-epoxide have the potential to exacerbate seizures. Among psychotropic agents, viloxazine [124], trazodone [125], fluoxetine [126] and fluvoxamine [127] have been reported to increase carbamazepine concentrations. Newer antipsychotic agents are weak inhibitors of CYP450 enzymes and are unlikely to have a significant effect on carbamazepine levels.…”

Section: Mood-stabilising Antiepileptic Drugsmentioning

confidence: 99%

Risk of seizures associated with psychotropic medications: emphasis on new drugs and new findings

Lee¹,

Finley²,

Alldredge³

2003

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Psychotropic medications in the classes of antidepressants, antipsychotics and mood stabilisers have been recognised in the literature and clinical settings as having high epileptogenic potential. Among these three classes, clozapine, tricyclic antidepressants (TCAs) and lithium are agents that clinicians have historically recognised as precipitants of drug-induced seizures. There are few reports that review the epileptogenic risk of newer psychotropic agents; in this qualitative review, the authors provide an update on the most recently published reports on seizures associated with antidepressants, antipsychotics, mood stabilisers, anxiolytics and sedative-hypnotics. In general, the epileptogenic risks of the newer psychotropic agents appear to be quite low as long as dosing strategies are consistent with recommended guidelines. Whilst newer psychotropic medications appear to be safe in patients with epilepsy, few studies have specifically addressed this population. In addition, the potential for drug interactions between antiepileptic drugs and psychotropics may be substantial with certain agents. For example, many psychotropes are both substrates and inhibitors of cytochrome P450 (CYP450) isoenzymes, whilst many antiepileptic drugs are both substrates and inducers of CYP450 activity. Every attempt should be made to minimise potential interactions when these agents are concomitantly administered.

show abstract

Interaction between carbamazepine and fluvoxamine

Cited by 77 publications

References 6 publications

Depression in Epilepsy: A Common but Often Unrecognized Comorbid Malady

Depression in Epilepsy: A Common but Often Unrecognized Comorbid Malady

Depression in Epilepsy: Etiology, Phenomenology, and Treatment

Risk of seizures associated with psychotropic medications: emphasis on new drugs and new findings

Contact Info

Product

Resources

About